|Grant Number:||5R01CA120562-05 Interpret this number|
|Primary Investigator:||Boudreau, Denise|
|Organization:||Group Health Cooperative|
|Project Title:||Commonly Used Medications and Breast Cancer Recurrence|
DESCRIPTION (provided by applicant): Breast cancer is the most frequently diagnosed cancer in women and it is the second most common cause of cancer mortality. Breast cancer incidence rates have continued to rise since 1980, while mortality rates have declined. As a result, more women are at risk for breast cancer recurrences. Recurrences have important negative consequences requiring a variety of palliative treatments and often lead to death. Numerous commonly used medications such as such as, statins, antihypertensives, antidepressants, and antibiotics have been hypothesized to alter breast cancer risk, in many cases, there is strong biologic evidence to support these hypotheses. However, no studies have examined how these commonly used medications are associated with risk of breast cancer recurrence. We propose to test the hypotheses that use of statins and ACE inhibitors will be associated with a reduced risk of recurrence, and use of antidepressants, antibiotics, calcium channel blockers, and diuretics will be associated with an increased risk of recurrence. To test these hypotheses, we will conduct a retrospective cohort study among approximately 4,550 women diagnosed between 1990 and 2008 with incident early stage invasive breast carcinoma, while enrolled at Group Health Cooperative, a large Health Maintenance Organization in western Washington State. We will use medical records and automated administrative data to follow women an average of 10 years to assess risk of breast cancer recurrence and to collect information on medication use and indication for use, primary therapy, and co-morbidities. Determining whether use of these drugs impacts breast cancer recurrence is of considerable public health importance given the widespread and increasing use of the medications under study and the burden of breast cancer in our nation. The hypotheses we are seeking to test are in line with the National Cancer Institute's 2015 goals of eliminating the suffering and death due to cancer. Learning more about whether there are factors that influence recurrence will help us with the secondary prevention of breast cancer and will lead to a reduction in breast cancer morbidity and mortality.
Metabolic syndrome and outcomes following early-stage breast cancer.
Authors: Calip GS, Malone KE, Gralow JR, Stergachis A, Hubbard RA, Boudreau DM
Source: Breast Cancer Res Treat, 2014 Nov;148(2), p. 363-77.
EPub date: 2014 Oct 10.
Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment.
Authors: Calip GS, Hubbard RA, Stergachis A, Malone KE, Gralow JR, Boudreau DM
Source: Pharmacoepidemiol Drug Saf, 2014 Jun 13;null, p. null.
EPub date: 2014 Jun 13.
Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer.
Authors: Boudreau DM, Yu O, Chubak J, Wirtz HS, Bowles EJ, Fujii M, Buist DS
Source: Breast Cancer Res Treat, 2014 Apr;144(2), p. 405-16.
EPub date: 2014 Feb 21.
Using natural language processing to improve efficiency of manual chart abstraction in research: the case of breast cancer recurrence.
Authors: Carrell DS, Halgrim S, Tran DT, Buist DS, Chubak J, Chapman WW, Savova G
Source: Am J Epidemiol, 2014 Mar 15;179(6), p. 749-58.
EPub date: 2014 Jan 30.
Factors associated with long-term adherence to annual surveillance mammography among breast cancer survivors.
Authors: Wirtz HS, Boudreau DM, Gralow JR, Barlow WE, Gray S, Bowles EJ, Buist DS
Source: Breast Cancer Res Treat, 2014 Feb;143(3), p. 541-50.
EPub date: 2014 Jan 10.
Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival.
Authors: Chubak J, Boudreau DM, Wirtz HS, McKnight B, Weiss NS
Source: J Natl Cancer Inst, 2013 Oct 2;105(19), p. 1456-62.
EPub date: 2013 Aug 12.
Frequent antibiotic use and second breast cancer events.
Authors: Wirtz HS, Buist DS, Gralow JR, Barlow WE, Gray S, Chubak J, Yu O, Bowles EJ, Fujii M, Boudreau DM
Source: Cancer Epidemiol Biomarkers Prev, 2013 Sep;22(9), p. 1588-99.
EPub date: 2013 Jul 5.
Time scale in follow-up studies: considering disease prognosis.
Authors: Chubak J, Yu O, Buist DS, Wirtz HS, Boudreau DM
Source: Epidemiology, 2013 Jul;24(4), p. 628-9.
Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer.
Authors: Aiello Bowles EJ, Boudreau DM, Chubak J, Yu O, Fujii M, Chestnut J, Buist DS
Source: J Oncol Pract, 2012 Nov;8(6), p. e149-57.
EPub date: 2012 Jul 17.
Bone mineral density screening among women with a history of breast cancer treated with aromatase inhibitors.
Authors: Spangler L, Yu O, Loggers E, Boudreau DM
Source: J Womens Health (Larchmt), 2013 Feb;22(2), p. 132-40.
EPub date: 2013 Jan 30.
Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment.
Authors: Calip GS, Boudreau DM, Loggers ET
Source: Breast Cancer Res Treat, 2013 Feb;138(1), p. 225-33.
EPub date: 2013 Jan 29.
Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer.
Authors: Chubak J, Yu O, Pocobelli G, Lamerato L, Webster J, Prout MN, Ulcickas Yood M, Barlow WE, Buist DS
Source: J Natl Cancer Inst, 2012 Jun 20;104(12), p. 931-40.
EPub date: 2012 Apr 30.
Cost of breast-related care in the year following false positive screening mammograms.
Authors: Chubak J, Boudreau DM, Fishman PA, Elmore JG
Source: Med Care, 2010 Sep;48(9), p. 815-20.
Statin use and cancer risk: a comprehensive review.
Authors: Boudreau DM, Yu O, Johnson J
Source: Expert Opin Drug Saf, 2010 Jul;9(4), p. 603-21.